Abstract

Comparing metagenomic samples is crucial for understanding microbial communities. For different groups of microbial communities, such as human gut metagenomic samples from patients with a certain disease and healthy controls, identifying group-specific sequences offers essential information for potential biomarker discovery. A sequence that is present, or rich, in one group, but absent, or scarce, in another group is considered “group-specific” in our study. Our main purpose is to discover group-specific sequence regions between control and case groups as disease-associated markers. We developed a long k-mer (k ≥ 30 bps)-based computational pipeline to detect group-specific sequences at strain resolution free from reference sequences, sequence alignments, and metagenome-wide de novo assembly. We called our method MetaGO: Group-specific oligonucleotide analysis for metagenomic samples. An open-source pipeline on Apache Spark was developed with parallel computing. We applied MetaGO to one simulated and three real metagenomic datasets to evaluate the discriminative capability of identified group-specific markers. In the simulated dataset, 99.11% of group-specific logical 40-mers covered 98.89% disease-specific regions from the disease-associated strain. In addition, 97.90% of group-specific numerical 40-mers covered 99.61 and 96.39% of differentially abundant genome and regions between two groups, respectively. For a large-scale metagenomic liver cirrhosis (LC)-associated dataset, we identified 37,647 group-specific 40-mer features. Any one of the features can predict disease status of the training samples with the average of sensitivity and specificity higher than 0.8. The random forests classification using the top 10 group-specific features yielded a higher AUC (from ∼0.8 to ∼0.9) than that of previous studies. All group-specific 40-mers were present in LC patients, but not healthy controls. All the assembled 11 LC-specific sequences can be mapped to two strains of Veillonella parvula: UTDB1-3 and DSM2008. The experiments on the other two real datasets related to Inflammatory Bowel Disease and Type 2 Diabetes in Women consistently demonstrated that MetaGO achieved better prediction accuracy with fewer features compared to previous studies. The experiments showed that MetaGO is a powerful tool for identifying group-specific k-mers, which would be clinically applicable for disease prediction. MetaGO is available at https://github.com/VVsmileyx/MetaGO.

Highlights

  • High-throughput sequencing technologies have ushered in new views of ubiquity and diversity of microbial communities (Yatsunenko et al, 2012)

  • Since sufficiently long k-mers are usually specific to a genome (Fofanov et al, 2004), we proposed a computational framework to identify group-specific sequences between two groups of metagenomic samples with long (≥30 bp) k-mers in this study

  • 4,452,553 (56.42%) of them were exactly matched to B. caccae ATCC 43185 and covered 99.61% of the whole genome, which is differentially abundant between the healthy control and the case groups

Read more

Summary

Introduction

High-throughput sequencing technologies have ushered in new views of ubiquity and diversity of microbial communities (Yatsunenko et al, 2012). Metagenomic sequencing data permit comprehensive profiling of microbial communities at singlenucleotide resolution. The ability to compare two groups of metagenomic samples is crucial for understanding microbial communities and their effects on hosts. For two groups of individuals, patients with a certain disease and healthy individuals, group-specific markers offer significant support in understanding and predicting disease. “Group-specific” focuses on the highest discriminative power, rather than the statistically significant difference (White et al, 2009; Segata et al, 2011), to classify, or predict, case and control groups. Prediction performance evaluates the discriminative capability of identified group-specific features

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.